Dakin, Helen A
Wordsworth, Sarah
Rogers, Chris A
Abangma, Giselle
Raftery, James
Harding, Simon P
Lotery, Andrew J
Downes, Susan M
Chakravarthy, Usha
Reeves, Barnaby C
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
https://doi.org/10.1136/bmjopen-2014-005094
Stroke Rates after Introduction of Vascular Endothelial Growth Factor Inhibitors for Macular Degeneration: A Time Series Analysis
https://doi.org/10.1016/j.ophtha.2012.05.028
Pharmacogenetic Associations with Vascular Endothelial Growth Factor Inhibition in Participants with Neovascular Age-related Macular Degeneration in the IVAN Study
https://doi.org/10.1016/j.ophtha.2013.07.046
Changes in intraocular pressure in study and fellow eyes in the IVAN trial
https://doi.org/10.1136/bjophthalmol-2015-307595
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
https://doi.org/10.1016/j.ophtha.2012.04.015
A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN) (Results)
https://doi.org/10.3310/hta19780
VEGFR2 Gene Polymorphisms and Response to Anti–Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration
https://doi.org/10.1016/j.ophtha.2015.04.024
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
https://doi.org/10.1016/s0140-6736(13)61501-9
Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial
https://doi.org/10.1136/bmjopen-2015-010685